REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Resources for you and your patients.

Bristol Myers Squibb is dedicated to helping patients start and continue REVLIMID treatment until disease progression or unacceptable toxicity.

Resources and tools for HCPs.

View HCP Resources
Female HCP
Female HCP
REVLIMID® Patient and Healthcare Provider
REVLIMID® Patient and Healthcare Provider

Explore resources to help your patients with MM.

View Patient Resources

REVLIMID is only available through a restricted distribution program called the Lenalidomide REMS program.

Learn about Lenalidomide REMS
HCP Looking into a Microscope
HCP Looking into a Microscope
HCP Discussing REVLIMID® Resources with Patient
HCP Discussing REVLIMID® Resources with Patient

REVLIMID is only available through a select network of specialty pharmacies.

See Specialty Pharmacy Network

  • MM, multiple myeloma.

Looking for resources to help manage your patients on REVLIMID?

Get Tools and Resources